Prognostic significance of BMP and activin membrane-bound inhibitor in colorectal cancer

作     者：Nozomi Togo Susumu Ohwada Shinji Sakurai Hiroyuki Toya Ichiro Sakamoto Tatsuya Yamada Tetsuhiro Nakano Ken Muroya Izumi Takeyoshi Takashi Nakajima Takashi Sekiya Yusuke Yamazumi Tsutomu Nakamura Tetsu Akiyama 

作者机构：Departments of Surgery Graduate School of Medicine Gunma University Gunma 371-8511 Japan Departments of Tumor Pathology Graduate School of Medicine Gunma University Gunma 371-8511 Japan Laboratory of Molecular and Genetic Information Institute for Molecular and Cellular Biosciences University of Tokyo Tokyo 113-0032 Japan 

出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)

年 卷 期：2008年第14卷第31期

页      面：4880-4888页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Grants from the Japan Science and Technology Agency, No. 17014011 The Harunasou Foundation Cancer Research Subsidizing Fund The Kanetsu Chuo Hospital Research Fund research funds from the Uchida Clinic in Inamachi, Saitama The Katoh Clinic, Maebashi Norte Hospital in Maebashi, Gunma Keiaido Hospital in Midori, Gunma 

主　　题：BMP and activin membrane-bound inhibitor Colorectal cancer Transforming growth factor-beta signal Prognosis Wnt signal 

摘      要：AIM： To investigate the clinical significance of BMP and activin membrane-bound inhibitor （BAMBI） which is a pseudoreceptor of transforming growth factorbeta （TGF-β） type 1 receptors and acts as a negative regulator of TGF-β signaling and expression aberrantly elevated in colorectal cancers （CRCs）. We studied BAMBI expression in CRCs. METHODS： We studied BAMBI expression in 183 surgically resected CRCs by immunochemical and immunoblotting analyses using a generated monoclonal anti-BAMBI antibody. Commercially available anti-β- catenin and anti-p53 antibodies were also applied for immunochemical analyses as a comparison ***： Immunohistochemical analysis revealed that BAMBI expression was observed in 148 （80.8%）, and strong BAMBI expression was observed in 46% of the CRCs. Strong BAMBI expression was positively correlated with histological type, depth of invasion, lymph node metastases, and tumor node metastasis （TNM） stage （P 〈 0.05）. Clear associations were found between BAMBI and β-catenin （P = 0.035） and p53 （P =0.049） expression. In curatively resected CRC, 5-year recurrence-free survival was 51.9% （P = 0.037） for strong BAMBI expression compared to 79.8% for weak BAMBI expression. In the Cox＇s multivariate analysis, lymph node metastases （relative risk 6.685; P 〈 0.001） and depth of invasion （RR 14.0; P = 0.013） were significant indicators for recurrence, and strong BAMBI expression （RR 2.26; P = 0.057） tended to be significant. CONCLUSION： BAMBI was linked to a potentially aggressive tumor phenotype and predicted tumor recurrence and cancer-related death in CRC. BAMBI expression might be applicable in the routine clinical setting of CRC.